Hemogenyx Pharmaceuticals PLC Announces the Approval and Issuance of U.S. Conditioning Patent

Rhea-AI Summary

Hemogenyx Pharmaceuticals plc (LSE:HEMO) has announced the approval and issuance of a U.S. Conditioning Patent for a method of eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) in a patient using Bi-Specific Antibodies. The CEO, Dr. Vladislav Sandler, expressed excitement about the decision, emphasizing the significance of this patent protection for CDX, one of the company's key product candidates for the future. This development reinforces the company's position as a leader in the area of conditioning bone marrow transplants.

Approval and Issuance of U.S. Conditioning Patent

LONDON, UK / ACCESSWIRE / February 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that a patent application entitledMethod of Eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) In A Patient Using Bi-Specific Antibodieshas been allowed to be issued as a patent by the United States Patent and Trademark Office.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"I am excited by the decision of the United States Patent and Trademark Office to allow this patent application. This is a significant addition to the patent protection for CDX which remains one of our key product candidates for the future. This also solidifies our Company's position as a leader in the area of conditioning bone marrow transplants".

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	Peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on accesswire.com

What is the ticker symbol for Hemogenyx Pharmaceuticals plc?

The ticker symbol for Hemogenyx Pharmaceuticals plc is HEMO.

What is the significance of the U.S. Conditioning Patent for Hemogenyx Pharmaceuticals plc?

The U.S. Conditioning Patent allows the company to protect its method of eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors using Bi-Specific Antibodies, reinforcing its position as a leader in the area of conditioning bone marrow transplants.

Who is the CEO of Hemogenyx Pharmaceuticals plc?

The CEO of Hemogenyx Pharmaceuticals plc is Dr. Vladislav Sandler.

What is the key product candidate mentioned in the press release?

The key product candidate mentioned is CDX, for which the patent protection is significant.

What is the contact information for Hemogenyx Pharmaceuticals plc?

For inquiries, you can contact the company at headquarters@hemogenyx.com or Peter.redmond@hemogenyx.com.

What is the contact information for SP Angel Corporate Finance LLP?

You can contact SP Angel Corporate Finance LLP at +44 (0)20 3470 0470.

What is the contact information for Peterhouse Capital Limited?

You can contact Peterhouse Capital Limited at +44 (0)20 7469 0930.